Änderungen von Dokument Pustulosis subcornealis Sneddon-Wilkinson
Zuletzt geändert von Thomas Brinkmeier am 2025/04/25 20:40
<
>
bearbeitet von Thomas Brinkmeier
am 2022/01/02 21:50
am 2022/01/02 21:50
bearbeitet von Thomas Brinkmeier
am 2019/02/02 21:13
am 2019/02/02 21:13
Änderungskommentar:
Es gibt keinen Kommentar für diese Version
Zusammenfassung
Details
- Varia, Pustulosis subcornealis Sneddon-Wilkinson, Arch Inflamm, 2016.pdf
-
- Author
-
... ... @@ -1,1 +1,0 @@ 1 -XWiki.Dermatologie_Kompendium - Größe
-
... ... @@ -1,1 +1,0 @@ 1 -620.9 KB - Inhalt
- Wikiderm.EntryClass[0]
-
- Eintrag
-
... ... @@ -65,45 +65,9 @@ 65 65 (% class="Feature" %)Bsp:(%%) Mycoplasma pneumoniae, HIV 66 66 67 67 (% class="Eintrag-2" %) 68 -(% class="Feature" %)DD:(%%) (% class=" Bullet" %)-(%%) (% class="Abbreviation" %)AGEP(%%)68 +(% class="Feature" %)DD:(%%) (% class="Abbreviation" %)AGEP(%%), Dermatitis herpetiformis, eosinophile pustulöse Follikulitis Ofuji, Impetigo contagiosa, Pemphigus foliaceus, Psoriasis pustulosa 69 69 70 -(% class="Ebene-1" %) 71 -(% class="Bullet" %)-(%%) Dermatitis herpetiformis 72 - 73 -(% class="Ebene-1" %) 74 -(% class="Bullet" %)-(%%) eosinophile pustulöse Follikulitis Ofuji 75 - 76 -(% class="Ebene-1" %) 77 -(% class="Bullet" %)-(%%) Impetigo contagiosa 78 - 79 -(% class="Ebene-1" %) 80 -(% class="Bullet" %)-(%%) Pemphigus foliaceus 81 - 82 82 (% class="Eintrag-2" %) 83 - 84 - 85 -(% class="Ebene-1" %) 86 -(% class="Bullet" %)-(%%) Psoriasis pustulosa 87 - 88 -(% class="Ebene-1" %) 89 -(% class="Bullet" %)-(%%) Tinea incognito 90 - 91 -(% class="Ebene-2" %) 92 -(% class="Feature" %)Lit:(%%) [[Kalkan, G., Demirseren, D. D, Güney, C. A, & Aktaş, A. (2020). A case of tinea incognito mimicking subcorneal pustular dermatosis. Dermatology Online Journal, 26(2)>>url:https://escholarship.org/uc/item/46g9x55w]] 93 - 94 -(% class="Eintrag-2" %) 95 -(% class="Feature" %)Lit:(%%) (% class="Bullet" %)-(%%) {{pdfbox Datei="Varia, Pustulosis subcornealis Sneddon-Wilkinson, Arch Inflamm, 2016.pdf" /}} 96 - 97 -(% class="Ebene-1" %) 98 -(% class="Bullet" %)-(%%) Open Access Maced J Med Sci. 2020 Jun 05; 8(T1):12-15. [[https:~~/~~/doi.org/10.3889/oamjms.2020.4870>>url:https://doi.org/10.3889/oamjms.2020.4870]] 99 - 100 -(% class="Ebene-1" %) 101 -(% class="Bullet" %)-(%%) International Journal of Women's Dermatology, Volume 6, Issue 3, 2020, Pages 131-136, ISSN 2352-6475, [[https:~~/~~/doi.org/10.1016/j.ijwd.2020.02.003>>url:https://doi.org/10.1016/j.ijwd.2020.02.003]] 102 - 103 -(% class="Ebene-1" %) 104 -(% class="Bullet" %)-(%%) SAGE Open Med Case Rep. 2019 Jan 30;7:2050313X19826432. [[http:~~/~~/doi.org/10.1177/2050313X19826432>>url:http://doi.org/10.1177/2050313X19826432]] 105 - 106 -(% class="Eintrag-2" %) 107 107 (% class="Feature" %)Th:(%%) (% class="Bullet" %)-(%%) lokal 108 108 109 109 (% class="Ebene-2" %) ... ... @@ -110,12 +110,6 @@ 110 110 (% class="Bullet" %)-(%%) Farbstoffe (**[[Antiseptika]]**) 111 111 112 112 (% class="Ebene-2" %) 113 -(% class="Bullet" %)-(%%) Mometasonfuroat 114 - 115 -(% class="Ebene-3" %) 116 -(% class="Feature" %)Lit:(%%) Dermatol Ther. 2021 Nov 27:e15235. [[http:~~/~~/doi.org/10.1111/dth.15235>>url:http://doi.org/10.1111/dth.15235]] 117 - 118 -(% class="Ebene-2" %) 119 119 (% class="Bullet" %)-(%%) Tacalcitol 120 120 121 121 (% class="Ebene-3" %) ... ... @@ -133,12 +133,6 @@ 133 133 (% class="Ebene-5" %) 134 134 (% class="Feature" %)Lit:(%%) (% class="Abbreviation" %)CR(%%) 135 135 136 -(% class="Ebene-2" %) 137 -(% class="Bullet" %)-(%%) Dapson Gel 138 - 139 -(% class="Ebene-3" %) 140 -(% class="Feature" %)Lit:(%%) J Dermatol. 2019 Jun 24. [[http:~~/~~/doi.org/10.1111/1346-8138.14953>>url:http://doi.org/10.1111/1346-8138.14953]] 141 - 142 142 (% class="Ebene-1" %) 143 143 (% class="Bullet" %)-(%%) systemisch 144 144 ... ... @@ -182,12 +182,6 @@ 182 182 (% class="Feature" %)Lit:(%%) Dermatol Ther. 2019 Jan 14:e12818. [[http:~~/~~/doi.org/10.1111/dth.12818>>url:http://doi.org/10.1111/dth.12818]] 183 183 184 184 (% class="Ebene-2" %) 185 -(% class="Bullet" %)-(%%) Apremilast 186 - 187 -(% class="Ebene-3" %) 188 -(% class="Feature" %)Lit:(%%) Australas J Dermatol. 2020 Feb 11. [[http:~~/~~/doi.org/10.1111/ajd.13253>>url:http://doi.org/10.1111/ajd.13253]] 189 - 190 -(% class="Ebene-2" %) 191 191 (% class="Bullet" %)-(%%) Anti-TNF-alpha 192 192 193 193 (% class="Ebene-3" %) ... ... @@ -194,9 +194,7 @@ 194 194 (% class="Feature" %)Stoff:(%%) (% class="Bullet" %)-(%%) **[[Infliximab]]** 195 195 196 196 (% class="Ebene-4" %) 197 -{{pharMacro style="Ebene-4"}} 198 198 (% class="Feature" %)Phar:(%%) Remicade^^®^^ 199 -{{/pharMacro}} 200 200 201 201 (% class="Ebene-4" %) 202 202 (% class="Feature" %)Dos:(%%) 5 mg/kg i.v. ... ... @@ -211,11 +211,4 @@ 211 211 (% class="Feature" %)Lit:(%%) Ann Dermatol Venereol. 2013 Dec;140(12):797-800 (Frankreich) 212 212 213 213 (% class="Ebene-5" %) 214 -(% class="Feature" %)PT:(%%) (% class="Abbreviation" %)CR(%%) 215 - 216 -(% class="Ebene-2" %) 217 -(% class="Bullet" %)-(%%) Guselkumab 218 - 219 -(% class="Ebene-3" %) 220 -(% class="Feature" %)Lit:(%%) Int J Dermatol. 2021 Apr;60(4):e153-e154. [[http:~~/~~/doi.org/10.1111/ijd.15311>>url:http://doi.org/10.1111/ijd.15311]] 221 - 158 +(% class="Feature" %)PT:(%%) CR